- _ I NOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN (NIDPOE)
|
|
- Theresa Pierce
- 5 years ago
- Views:
Transcription
1 ~, ascxvrcr f, e 3 0 DEPARTMENT OF HEALTH & HUMAN SERVICES Pub l i c Hea l th Serv i ce Food and Drug Admi n i st ra t i on Rockv i l l e, MD NOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN (NIDPOE) CERTIFIED MAIL - RESTRICTED DELIVERY RETURN RECEIPT REQUESTED Stephen D. Rossner, M.D. 97 Barnes Road Wa l l i ngford, CT Dear Dr. Rossner : Be tween March 4 and 10, 2005, Ms. Pa t r i c i a Murphy and Ms. M i che l l e Noe, represent i ng the Food and Drug Admi n i st ra t i on (FDA), conduc ted an i nvest i ga t i on and me t w i th you to rev i ew your conduc t of the fo l l ow i ng c l i n i ca l i nvest i ga t i on : Protoco l L ]ent i t l ed, "Ef fec ts of Blood Pressure Reduc t i on on H i gh Sens i t i v i ty_c-reac t i ve Prote i n (hscrp) : A Mu l t i center, Randomi zed, Open-Labe l, 2- Arm Para l l e l Group to Eva l ua te the Ef f i cacy of Modera te vs. Aggress i ve Ant i hyper tens i ve Therapy w i thl JandC ] to Reduce Blood Pressure and P l asma hscrp l eve l s. i n Pa t i ents w i th Stage 2 Hyper tens i on. " Th i s study of the i nvest i ga t i ona l drug L. 1was conduc ted by you for - _ I Th i s i nspec t i on i s a par t of the FDA' s Bioresearch Mon i tor i ng Program, wh i ch i nc l udes i nspec t i ons des i gned to eva l ua te the conduc t of research and to ensure tha t the r i ghts, sa fety, and we l fare of the human sub j ec ts par t i c i pa t i ng i n c l i n i ca l research have been protec ted. We are aware tha t a t the conc l us i on of the i nspec t i on, Ms. Murphy and Ms. Noe presented and d i scussed w i th you Form FDA 483. We have eva l ua ted the i nspec t i on repor t, the documents submi t ted w i th the repor t, other per t i nent i nforma t i on obta i ned by the Agency, and your March 23, 2005 wr i t ten response to the Form FDA 483, addressed to the D i st r i c t Of f i ce D i rec tor, Ms. Ga i l Coste l l o. Based on our eva l ua t i on of th i s i nforma t i on, FDA' s Center for Drug Eva l ua t i on and Research ( the Center ) be l i eves tha t you have repea ted l y or de l i bera te l y v i o l a ted federa l regu l a t i ons govern i ng the conduc t of c l i n i ca l stud i es i nvo l v i ng i nvest i ga t i ona l new drugs and the protec t i on of human sub j ec ts under T i t l e 21, Code of Federa l Regu l a t i ons (CFR), Par ts
2 Page 2- -Dr. Rossner 312 and Par t 50 (copy enc l osed), and tha t you submi t ted fa l se i nforma t i on i n a requ i red repor t to the sponsor. Th i s l e t ter prov i des you w i th wr i t ten not i ce of the ma t ters under comp l a i nt and i n i t i a tes an admi n i st ra t i ve proceed i ng, descr i bed be l ow, to de termi ne whe ther you shou l d be d i squa l i f i ed f rom rece i v i ng i nvest i ga t i ona l drugs as se t for th under 21 CFR A l i st i ng of the ma j or v i o l a t i ons fo l l ows. The app l i cab l e prov i s i ons of the CFR are c i ted for each v i o l a t i on. 1. You submi t ted fa l se i nforma t i on to the sponsor i n a requ i red repor t [21 CFR (a) ]. a. b. You fa l s i f i ed i nformed consent documents and case repor t forms (CRFs) to i nd i ca te tha t sub j ec ts had prov i ded wr i t ten i nformed consent when sub j ec ts had not prov i ded such consent. In an a f f i dav i t comp l e ted by you dur i ng FDA' s i nspec t i on (da ted March 8, 2005), you admi t ted tha t sub j ec ts 001, 002, and 004 had not s i gned the i nformed consent documents and tha t you had s i gned these sub j ec ts ' names on the i nformed consent documents some t i me a f ter the sub j ec ts were enro l l ed i n the study ( i. e., tha t the sub j ec ts had not prov i ded wr i t ten i nformed consent ). In add i t i on, on the Vi s i t 1/Day 0 Inc l us i on/exc l us i on CRF tha t you submi t ted to the sponsor, you checked the box marked " yes " to i nd i ca te tha t sub j ec ts 001, 002, and 004 hadprov i ded wr i t ten i nformed consent to par t i c i pa te i n the study. The protoco l requ i red tha t the sub j ec ts be randomi zed to rece i ve e i therc 160 mg da i l y or J 160/12.5 mg da i l y for 2 weeks, and a f ter 2 weeks those rece i v i ng[_ were to have the i r dose i ncreased to 320 m and those rece i v i ngc were to have the i r dose i ncreased to[ ~320/12.5 mg for a dura t i on of 4 weeks. As descr i bed i n grea ter de ta i l be l ow, you fa l s i f i ed CRFs to i nd i ca te tha t sub j ec ts were randomi zed to rece i ve study drug i n accordance w i th these protoco l requ i rements, when i n fac t these sub j ec ts were admi n i stered study drug i n a manner i ncons i stent w i th these requ i rements. In an a f f i dav i t comp l e ted by you dur i ng the i nspec t i on, you admi t ted tha t sub j ec ts d i d not a l ways take the protoco l - requ i red dose and tha t, i n some cases, you spec i f i ca l l y i nst ruc ted sub j ec ts to take hal f the protoco l - requ i red dose. The fo l l ow i ng CRFs were submi t ted to the sponsor : i ) i i ) The Vi s i t 1/Day 0 CRF i nd i ca tes tha t sub j ec t 001 was randomi zed to rece i ve 160/12.5 mg and the Vi s i t 2/Week 2 and Vi s i t 3/week 6 CRFs i nd i ca te tha t the sub j ec t ' s dose was i ncreased to L '320/12.5 mg for the requ i red 4 week per i od. However, source med i ca l records i nd i ca te tha t the sub j ec t was dosed w i th[ J 80 mg and[ ]25 mg da i l y a t study v i s i t 1 and the dose of [ ' was i ncreased to 160 mg a t study v i s i t 2. The Vi s i t 1/Day 0 CRF i nd i ca tes tha t sub j ec t 002 was randomi zed to rece i ve J160 mg and the Vi s i t 2/Week 2 and Vi s i t 3/week 6 CRFs i nd i ca te tha t
3 Page 3- -Dr. Rossner the sub j ec t ' s dose was i ncreased to[ 1320 mg for the requ i red 4 week per i od. However, source med i ca l records i nd i ca te tha t the sub j ec t was dosed w i th[ ]80 mg and[ ]12.5 mg da i l y a t study v i s i t 1. There i s no documentat i on i n source records to i nd i ca te tha t th i s dose was changed a t any t i me dur i ng the study. i i i ) The Vi s i t 1/Day 0 CRT i nd i ca tes tha t sub j ec t C )was randomi zed to rece i ve 1160 mg and the Vi s i t 2/Week 2 and Vi s i t 3/Week 6 CRFs i nd i ca te tha t the sub j ec t ' s dose was i ncreased to 320 mg for the requ i red 4 week per i od. However, source med i ca l records i nd i ca te tha t the sub j ec t was dosed w i th J 80/12.5 mg da i l y a t study v i s i t 1. There i s no documentat i on i n source records to i nd i ca te tha t th i s dose was changed a t any t i me dur i ng the study. c. To be enro l l ed i n the study, the protoco l requ i red tha t study sub j ec ts mee t the protoco l -spec i f i ed cr i ter i a for hyper tens i on- - the mean of three (3) repea ted sea ted ' measurements of systo l i c b l ood pressure of 160 to 185 mm Hg, i nc l us i ve, and/or d i asto l i c b l ood pressure of 100 to 109 mm Hg, i nc l us i ve. As descr i bed i n grea ter de ta i l be l ow, there were d i screpanc i es be tween the b l ood pressure read i ngs recorded i n the CRFs and the source med i ca l records a t Vi s i t 1 for sub j ec ts 001, 002, 003, and 004. In an a f f i dav i t comp l e ted by you dur i ng the i nspec t i on, you admi t ted tha t you recorded fa l se b l ood pressure read i ngs i n the v i s i t 1 CRFs so tha t sub j ec ts 001, 002, 003, and 004 wou l d appear to mee t the i nc l us i on cr i ter i on for hyper tens i on. The fo l l ow i ng CRFs were submi t ted to the sponsor : i ) In the Vi s i t 1/Day 0 Inc l us i on/exc l us i on CRF for sub j ec t 001, da ted 6/8/04, you recorded b l ood pressure read i ngs of 168/102 mi n Hg, 166/100 mm Hg, and 166/102 mm Hg and you checked the box marked " yes " to i nd i ca te tha t the sub j ec t me t the cr i ter i a for hyper tens i on as de f i ned by the protoco l. However, source med i ca l records for sub j ec t 001 for tha t same da te recorded a b l ood pressure read i ng of 150/80 mm Hg. i i ) In the Vi s i t 1/Day 0 Inc l us i on/exc l us i on CRF for sub j ec t 002, da ted 6/9/04, you recorded b l ood pressure read i ngs of 174/100 mm Hg, 170/100 mm Hg, and 170/100 mm Hg and you checked the box marked " yes " to i nd i ca te tha t the sub j ec t me t the cr i ter i a for hyper tens i on as de f i ned by the protoco l. However, source med i ca l records for sub j ec t 002 for tha t same da te recorded a b l ood pressure read i ng of 140/80 mm Hg. i i i ) In the Vi s i t 1/Day 0 Inc l us i on/exc l us i on CRF for sub j ec t 003, da ted 6/9/04, you recorded b l ood pressure read i ngs of 164/102 mm Hg, 160/102 mm Hg, and 164/100 mm Hg and you checked the box marked " yes " to i nd i ca te tha t the sub j ec t me t the cr i ter i a for hyper tens i on as de f i ned by the protoco l. However, source med i ca l records for sub j ec t 003 for tha t same da te recorded a b l ood pressure read i ng of 142/80mm Hg.
4 Page 4- -Dr. Rossner i v) In the Vi s i t 1/Day 0 Inc l us i on/exc l us i on CRF for sub j ec t 004, da ted 6/10/04, you recorded b l ood pressure read i ngs of 168/98 nun Hg, 164/100 mm Hg, and 164/100 mm Hg and you checked the box marked " yes " to i nd i ca te tha t the sub j ec t me t the cr i ter i a for hyper tens i on as de f i ned by the protoco l. However, source med i ca l records for sub j ec t 004 for tha t same da te recorded a b l ood pressure read i ng of 118/80 mm Hg. d. The protoco l requ i red tha t sub j ec ts who were onpharmaco l og i c ant i hyper tens i ve therapy w i th ang i otens i n conver t i ng enzyme (ACE) i nh i b i tors, ang i otens i n receptor b l ockers, a l dosterone b l ockers, or th i az i de d i ure t i cs (herea f ter "proh i b i ted ant i hyper tens i ve therapy " ) w i th i n 3 months pr i or to v i s i t 1 be exc l uded f rom the study. As descr i bed i n grea ter de ta i l be l ow, i n CRFs for sub j ec ts 001, 003, and 004 you i nd i ca ted tha t the sub j ec ts had not taken proh i b i ted ant i hyper tens i ve therapy dur i ng the 3 months pr i or to enro l l ment i n the study when source documents i nd i ca ted tha t sub j ec ts had been tak i ng proh i b i ted ant i hyper tens i ve therapy. In an a f f i dav i t comp l e ted by you dur i ng the i nspec t i on, you admi t ted tha t there were d i screpanc i es be tween CRFs and source med i ca l records concern i ng sub j ec ts ' past med i ca l h i stor i es and tha t cer ta i n sub j ec ts d i d not mee t the i nc l us i on cr i ter i a because they were cont ro l l ed on ant i hyper tens i ve med i ca t i on pr i or to enro l l ment. The fo l l ow i ng CRFs were submi t ted to the sponsor : i ) In the Vi s i t 1 /Day 0 Inc l us i on/exc l us i on CRF for sub j ec t 001, da ted 6/8/04, you checked the box marked "no" to i nd i ca te tha t the sub j ec t had not rece i ved proh i b i ted ant i hyper tens i ve therapy i n the 3 months pr i or to tha t da te. However ; source records for sub j ec t 001 da ted 4/26/04 i nd i ca te tha t the sub j ec t was on Ben i car (o l mesar tan medoxomi l ), an ang i otens i n receptor b l ocker, and hydroch l oroth i az i de, a th i az i de d i ure t i c. Records da ted 5/4/04 i nd i ca te tha t Ben i car was d i scont i nued on tha t da te, but th i s occur red we l l w i th i n the 3 month w i ndow. i i ) In the Vi s i t 1/Day 0 Inc l us i on/exc l us i on CRF for sub j ec t 003, da ted 6/9/04, you checked the box marked "no" to i nd i ca te tha t the sub j ec t had not rece i ved proh i b i ted ant i hyper tens i ve therapy i n the 3 months pr i or to tha t da te. However, source records for sub j ec t 003 da ted 4/28/04 i nd i ca te tha t the sub j ec t was prescr i bed D i ovan, an ang i otens i n receptor b l ocker, on tha t da te. i i i ) In the Vi s i t l /Day 0 Inc l us i on/exc l us i on CRF for sub j ec t 004, da ted 6/10/04, you checked the box marked "no" to i nd i ca te tha t the sub j ec t had not rece i ved proh i b i ted ant i hyper tens i ve therapy i n the 3 months pr i or to tha t da te. However, source records for sub j ec t 004 da ted 4/30/04 i nd i ca te tha t the sub j ec t was prescr i bed D i ovan, an ang i otens i n receptor b l ocker, on tha t da te. e. The protoco l requ i red tha t potent i a l sub j ec ts be exc l uded f rom the study i f cer ta i n l abora tory parame ters were outs i de the ranges spec i f i ed i n the protoco l i n the 3
5 Page 5- -Dr. Rossner months pr i or to v i s i t enro l l ment, i nc l ud i ng serum crea t i n i ne >2.Omg/dL and any serum AST or ALT e l eva t i on tha t i s tw i ce the upper l i mi t of norma l. As descr i bed i n grea ter de ta i l be l ow, our i nvest i ga t i on found tha t you d i d not obta i n a l l of the requ i red l abora tory va l ues for sub j ec ts enro l l ed i n the study. In an a f f i dav i t comp l e ted by you dur i ng the i nspec t i on, you admi t ted tha t you recorded fa l se i nforma t i on on the case repor t forms for sub j ec ts 001, 002, 003, and 004 to i nd i ca te tha t the cer ta i n l abora tory resu l ts me t e l i g i b i l i ty cr i ter i a when the requ i red l abora tory eva l ua t i ons had not been done. The fo l l ow i ng CRFs were submi t ted to the sponsor : i ) In the Vi s i t l /Day 0 Inc l us i on/exc l us i on CRF for sub j ec t 001, da ted 6/8/04, you checked the box marked "no" to i nd i ca te tha t the sub j ec t ' s l abora tory va l ues for serum AST and ALT were not outs i de the spec i f i ed ranges. However, a l abora tory repor t for sub j ec t 001 da ted 4/15/04 i nd i ca tes tha t serum AST and ALT test i ng was not done. There i s no other docurnentat i on of l abora tory test i ng hav i ng been donedur i ng the 3 month per i od pr i or to the sub j ec t ' s enro l l ment. i i ) In the Vi s i t l /Day 0 Inc l us i on/exc l us i on CRF for sub j ec t 002, da ted 6/9/04, you checked the boxes marked ' no" to i nd i ca te tha t the sub j ec t ' s l abora tory va l ues for serum crea t i n i ne and serum AST and ALT were not outs i de the spec i f i ed ranges. However, a l abora tory repor t for sub j ec t 002 da ted 6/9/04 i nd i ca tes tha t serum crea t i n i ne and serum AST and ALT test i ng were not done. There i s no other documentat i on of l abora tory test i ng hav i ng been done dur i ng the 3 month per i od pr i or to the sub j ec t ' s enro l l ment. i i i ) In the Vi s i t l /Day 0 Inc l us i on/exc l us i on CRF for sub j ec t 003, da ted 6/9/04, you checked the box marked "no" to i nd i ca te tha t the sub j ec t ' s l abora tory va l ues for serum AST and ALT were not outs i de the spec i f i ed ranges. However, a l abora tory repor t for sub j ec t 003 da ted 6/9/04 i nd i ca tes tha t serum AST and ALT test i ng was not done. There i s no other documentat i on of l abora tory test i ng hav i ng been done dur i ng the 3 month per i od pr i or to the sub j ec t ' s enro l l ment. i v) In the Vi s i t l /Day 0 Inc l us i on/exc l us i on CRF for sub j ec t 004, da ted 6/10/04, you checked the box marked "no" to i nd i ca te tha t the sub j ec t ' s l abora tory va l ues for serum AST and ALT were not outs i de the spec i f i ed ranges. However, a l abora tory repor t for sub j ec t 004 da ted 6/10/04 i nd i ca tes tha t serum AST and ALT test i ng was not done. There i s no other documentat i on of l abora tory test i ng hav i ng been done dur i ng the 3 month per i od pr i or to the sub j ec t ' s enro l l ment.
6 Page 6- -Dr. Rossner 2. You fa i l ed to obta i n the l ega l l y e f fec t i ve i nformed consent of sub j ec ts par t i c i pa t i ng i n the study [21 CFR 50.20, 50.27, and ]. An i nvest i ga tor i s respons i b l e for obta i n i ng the i nformed consent of each human sub j ec t to whom study drug i s admi n i stered i n accordance w i th the requ i rements of 21 CFR Par t 50 (see 21 CFR ). In par t i cu l ar, i nformed consent i s requ i red to be documented by use of a wr i t ten consent formed approved by an IRB 1 and s i gned and da ted by the sub j ec t or the sub j ec t ' s l ega l l y author i zed representat i ve a t the t i me of consent (21 CFR 50.27(a) ). Our i nvest i ga t i on found tha t, for sub j ec ts 001, 002, and 004, you d i d not document the i r i nformed consent by the use of a wr i t ten consent form s i gned and da ted by the sub j ec ts. Fur thermore, i n an a f f i dav i t comp l e ted by you dur i ng the i nspec t i on, you stated tha t you " verba l l y to l d the sub j ec ts about the study, " and admi t ted tha t you s i gned these sub j ec ts ' names on the i nformed consent documents some t i me a f ter the sub j ec ts had been enro l l ed i n the study. There fore, you d i d not obta i n the l ega l l y e f fec t i ve i nformed consent of sub j ec ts 001, 002, and You fa i l ed to ensure the stud i es were conduc ted accord i ng to the i nvest i ga t i ona l p l an [21 CFR ). a. The protoco l re u i red tha t the sub j ec ts be randomi zed to rece i ve e i ther t ~ 160 mg da i l y or ]160/12.5 mg da i l y for 2 weeks, and a f ter 2 weeks those rece i v i ng t to have the i r dose i ncreased to 320 m and those rece i v i ngl A were to have the i r dose i ncreased to~ 1320/12.5 mg for a dura t i on of 4 weeks. Sub j ec ts 001, 002, and 003 were not dosed i n accordance w i th the protoco l. (See v i o l a t i ons # l.b. i - i i i above. ) b. c. The protoco l requ i red tha t sub j ec ts mee t the protoco l -spec i f i ed cr i ter i a for hyper tens i on to be enro l l ed i n the study- - the mean of three (3) repea ted sea ted measurements of systo l i c b l ood pressure of 160 to 185 mm Hg, i nc l us i ve, and/or d i asto l i c b l ood pressure of 100 to 109 nun Hg, i nc l us i ve. Sub j ec ts 001, 002, 003, and 004 d i d not mee t the cr i ter i a for hyper tens i on spec i f i ed i n the protoco l, but were none the l ess enro l l ed i n the study. (See v i o l a t i ons # l. c. i - i v above. ) The protoco l exc l uded sub j ec ts who were on pharmaco l og i c ant i hyper tens i ve therapy w i th ang i otens i n conver t i ng enzyme (ACE) i nh i b i tors, ang i otens i n receptor b l ockers, a l dosterone b l ockers, or th i az i de d i ure t i cs wi th i n 3 months pr i or to v i s i t 1. Sub j ec ts 001, 003, and 004 were tak i ng proh i b i ted ant i hyper tens i ve therap i es w i th i n the 3 month per i od pr i or to v i s i t 1, but were none the l ess enro l l ed i n the study. (See v i o l a t i ons # l.d. i - i i i above. ) 1 Wr i t ten consent i s requ i red un l ess an IRB de termi nes there i s a bas i s to wa i ve the requ i rement for consent. wr i t ten To wa i ve the requ i rement an IRB must de termi ne tha t the study presents no more than r i sk mi n i ma l or the study mee ts the requ i rements for an except i on f rom i nform consent for emergency research CFR (c)Ne i ther except i on app l i es to Protoco l
7 Page 7- -Dr. Rossner d. The protoco l exc l uded sub j ec ts i f cer ta i n l abora tory parame ters were outs i de the protoco l -spec i f i ed ranges i n the 3 months pr i or to v i s i t 1, i nc l ud i ng serum crea t i n i ne >2.Omg/dL and any serum AST or ALT e l eva t i on tha t i s tw i ce the upper l i mi t of norma l. In an a f f i dav i t comp l e ted by you dur i ng the i nspec t i on, you acknow l edged tha t you d i d not obta i n resu l ts of cer ta i n requ i red l abora tory test i ng (serum crea t i n i ne and/or serum AST and ALT) a t study v i s i t 1, or w i th i n the 3 months pr i or to study v i s i t 1, for sub j ec ts 001, 002, 003, and 004. These sub j ec ts were none the l ess enro l l ed i n the study. (See v i o l a t i ons # l. e. i - i v above. ) 4. You fa i l ed to ma i nta i n adequa te and accura te case h i stor i es tha t record a l l observa t i ons and other da ta per t i nent to the i nvest i ga t i on on each sub j ec t [21 CFR (b) ]. a. The protoco l spec i f i ed tha t a l l concomi tant med i ca t i ons must be recorded on the Concomi tant Med i ca t i on/s i gn i f i cant Non-Drug Therap i es CRF. Our i nvest i ga t i on found tha t sub j ec ts 001, 002, 003, and 004 were tak i ng concomi tant med i ca t i ons dur i ng the study, but these med i ca t i ons were not recorded i n the appropr i a te CRFs. In an a f f i dav i t comp l e ted by you dur i ng the i nspec t i on, you acknow l edged tha t i nforma t i on on concomi tant med i ca t i ons recorded i n the CRFs d i d not a l ways ma tch i nforma t i on recorded i n source med i ca l records. For examp l e : i ) i i ) Source med i ca l records i nd i ca te tha t sub j ec t 001 was tak i ng Lopressor 25 mg da i l y dur i ng the study, but th i s i nforma t i on was not recorded i n the CRF. Source med i ca l records i nd i ca te tha t sub j ec t 002 was tak i ng L i p i tor dur i ng the study, but th i s i nforma t i on was not recorded i n the CRF. i i i ) Source med i ca l records i nd i ca te tha t sub j ec t 003 was tak i ng L i p i tor, and asp i r i n dur i ng the study, but th i s i nforma t i on was not recorded i n the CRF. i v) Source med i ca l records i nd i ca te tha t sub j ec t 004 was tak i ng Hyt r i n, Norvasc, hydroch l oroth i az i de, asp i r i n, and l ovastat i n dur i ng the study, but th i s i nforma t i on was not recorded i n the CRF. b. The protoco l requ i red tha t adverse events be recorded i n the Adverse Event CRF. The protoco l de f i nes " adverse event " as any undes i rab l e s i gn, symptom or med i ca l cond i t i on occur r i ng a f ter star t i ng study drug. Accord i ng to source med i ca l record for sub j ec t 001, the sub j ec t exper i enced d i zz i ness wh i l e on study med i ca t i on, but th i s adverse event was not recorded i n the Adverse Event CRF. c. Our i nvest i ga t i on found tha t the i n i t i a l s of four sub j ec ts enro l l ed i n the study were i naccura te. You recorded the fo l l ow i ng i n i t i a l s i n study documents (e.g., case repor t forms and i nformed consent documents) for the sub ' ec ts who were enro l l ed i n the study : 001 L J 002L ~003L ~and 004 J Dur i ng the i nspec t i on, you admi t ted tha t you enro l l ed sub j ec ts under d i f ferent i n i t i a l s and tha t
8 Page 8- -Dr. Rossner the cor rec t i n i t i a l s were those conta i ned i n the med i ca l records. The i n i t i a l s recorded i n the med i ca l records were as fo l l ows : 001 C 1002L ]003 ]and 004[ Th i s l e t ter i s not i ntended to be ana l l - i nc l us i ve l i st of de f i c i enc i es w i th your c l i n i ca l stud i es of i nvest i ga t i ona l produc ts. I t i s your respons i b i l i ty to ensure adherence to each requ i rement of the l aw and re l evant regu l a t i ons. On the bas i s of the above l i sted v i o l a t i ons, the Center asser ts tha t you have repea ted l y or de l i bera te l y fa i l ed to comp l y w i th the c i ted regu l a t i ons and submi t ted fa l se i nforma t i on to the sponsor i n a requ i red repor t. Your ac t i ons have exposed human sub j ec ts to unnecessary r i sks and j eopard i zed the i ntegr i ty of da ta. The Center proposes tha t you be d i squa l i f i ed as a cl i n i ca l i nvest i ga tor. You may rep l y to the above stated i ssues, i nc l ud i ng an exp l ana t i on of why you shou l d rema i n e l i g i b l e to rece i ve i nvest i ga t i ona l produc ts and not be d i squa l i f i ed as a c l i n i ca l i nvest i ga tor, i n a wr i t ten response or a t an i nforma l conference i n my of f i ce. Th i s procedure i s prov i ded for by regu l a t i on 21 CFR W i th i n f i f teen (15) days of rece i pt of th i s l e t ter, wr i te or ca l l me a t (301) to ar range a conference t i me or to i nd i ca te your i ntent to respond i n wr i t i ng. Shou l d you choose to respond i n wr i t i ng, your wr i t ten response must be forwarded w i th i n th i r ty (30) days of rece i pt of th i s l e t ter. Your rep l y shou l d be sent to : Joseph Sa l ewsk i D i rec tor (Ac t i ng) D i v i s i on of Sc i ent i f i c Invest i ga t i ons, HFD-45 Of f i ce of Med i ca l Po l i cy Center for Drug Eva l ua t i on and Research ' Food and Drug Admi n i st ra t i on 7520 Stand i sh P l ace, Room # 103 Rockv i l l e, Mary l and Shou l d you request an i nforma l conference, we ask tha t you prov i de us w i th a fu l l and comp l e te exp l ana t i on of the above l i sted v i o l a t i ons. You shou l d br i ng w i th you a l l per t i nent documents, and a representat i ve of your cho i ce may accompany you. Al though the conference i s i nforma l, a t ranscr i pt of the conference w i l l be prepared. I f you choose to proceed i n th i s manner, we p l an to ho l d such a conference w i th i n 30 days of your request. At any t i me dur i ng th i s admi n i st ra t i ve process, you may enter i nto a consent agreement w i th FDA regard i ng your future use of i nvest i ga t i ona l produc ts. Such an agreement wou l d termi na te th i s d i squa l i f i ca t i on proceed i ng. Enc l osed you w i l l f i nd a proposed agreement be tween you and the FDA.
9 Page 9- -Dr. Rossner The Center w i l l care fu l l y cons i der any ora l or wr i t ten response. I f your exp l ana t i on i s accepted by the Center, the d i squa l i f i ca t i on process w i l l be termi na ted. I f your wr i t ten or ora l responses to our a l l ega t i ons are unsa t i sfac tory, or we cannot come to terms on a consent agreement, or you do not respond to th i s not i ce, you w i l l be of fered a regu l a tory hear i ng be fore FDA, pursuant to 21 CFR 16 (enc l osed) and 21 CFR Be fore such a hear i ng, FDA w i l l prov i de you not i ce of the ma t ters to be cons i dered, i nc l ud i ng a comprehens i ve statement of the bas i s for the dec i s i on or ac t i on taken or proposed, and a genera l summary of the i nforma t i on tha t w i l l be presented by FDA i n suppor t of the dec i s i on or ac t i on. A pres i d i ng of f i cer f ree f rom b i as or pre j ud i ce and who has not par t i c i pa ted i n th i s ma t ter w i l l conduc t the hear i ng. Such a hear i ng w i l l de termi ne whe ther or not you w i l l rema i n ent i t l ed to rece i ve i nvest i ga t i ona l produc ts. You shou l d be aware tha t ne i ther ent ry i nto a consent agreement nor pursu i t of a hear i ng prec l udes the poss i b i l i ty of a coro l l ary j ud i c i a l proceed i ng or admi n i st ra t i ve remedy concern i ng these v i o l a t i ons. S i ncere l y yours, {See appended e l ec t ron i c s i gna ture page } Joseph Sa l ewsk i D i rec tor (Ac t i ng) D i v i s i on of Sc i ent i f i c Invest i ga t i ons, HFD-45 Of f i ce of Med i ca l Po l i cy Center for Drug Eva l ua t i on and Research Enc l osures : CFR CFR Consent Agreement
10 g ned e l ec t ron i ca l l y and Th i s i s a representat i on of an e l ec t ron i c record tha t was s i th i s page i s the man i festat i on of the e l ec t ron i c s i gna ture / s / Joseph Sa l ewsk i 5/10/ :46 :00 PM
WARNING LETTER. used i
DEPARTMENT OF HEALTH & HUMAN SERVICES Pub l i c Hea l th Serv i ce Food and Drug Admi n i st ra t i on OCT 7 2005 Center for Dev i ces and Rad i o l og i ca l Hea l th WARNING LETTER 2098 Ga i ther Road
More informationA L A BA M A L A W R E V IE W
A L A BA M A L A W R E V IE W Volume 52 Fall 2000 Number 1 B E F O R E D I S A B I L I T Y C I V I L R I G HT S : C I V I L W A R P E N S I O N S A N D TH E P O L I T I C S O F D I S A B I L I T Y I N
More informationP a g e 5 1 of R e p o r t P B 4 / 0 9
P a g e 5 1 of R e p o r t P B 4 / 0 9 J A R T a l s o c o n c l u d e d t h a t a l t h o u g h t h e i n t e n t o f N e l s o n s r e h a b i l i t a t i o n p l a n i s t o e n h a n c e c o n n e
More informationOH BOY! Story. N a r r a t iv e a n d o bj e c t s th ea t e r Fo r a l l a g e s, fr o m th e a ge of 9
OH BOY! O h Boy!, was or igin a lly cr eat ed in F r en ch an d was a m a jor s u cc ess on t h e Fr en ch st a ge f or young au di enc es. It h a s b een s een by ap pr ox i ma t ely 175,000 sp ect at
More informationT h e C S E T I P r o j e c t
T h e P r o j e c t T H E P R O J E C T T A B L E O F C O N T E N T S A r t i c l e P a g e C o m p r e h e n s i v e A s s es s m e n t o f t h e U F O / E T I P h e n o m e n o n M a y 1 9 9 1 1 E T
More informationDetect i on of Bra i n Damage in Psych i at r i c Popu l at i. Anton i o E. Puente. Depar tment of Psycho l ogy
Detect i on of Bra i n Damage in Psych i at r i c Popu l at i Anton i o E. Puente Depar tment of Psycho l ogy Un i vers i ty of Nor th Caro l i na - W i l m i ngton W i l m i ng t on, Nor th Caro l i na
More information176 5 t h Fl oo r. 337 P o ly me r Ma te ri al s
A g la di ou s F. L. 462 E l ec tr on ic D ev el op me nt A i ng er A.W.S. 371 C. A. M. A l ex an de r 236 A d mi ni st ra ti on R. H. (M rs ) A n dr ew s P. V. 326 O p ti ca l Tr an sm is si on A p ps
More informationSoftware Process Models there are many process model s in th e li t e ra t u re, s om e a r e prescriptions and some are descriptions you need to mode
Unit 2 : Software Process O b j ec t i ve This unit introduces software systems engineering through a discussion of software processes and their principal characteristics. In order to achieve the desireable
More informationP a g e 3 6 of R e p o r t P B 4 / 0 9
P a g e 3 6 of R e p o r t P B 4 / 0 9 p r o t e c t h um a n h e a l t h a n d p r o p e r t y fr om t h e d a n g e rs i n h e r e n t i n m i n i n g o p e r a t i o n s s u c h a s a q u a r r y. J
More informationSM6-36. adaptation instructions. auxiliary contacts on CS1 operating mechanism. English. distribution HTA
SM6-36 English distribution HTA adaptation instructions auxiliary contacts on CS operating mechanism SCHNEIDER ELECTRIC foreword symbols and conven ons you w ll f d all the symbols below throughout the
More informationProgression in calculations Years 5 and 6
Progression in calculations Years 5 and 6 Introduction At the centre of the mastery approach to the teaching of mathematics is the belief that all pupils have the potential to succeed. They should have
More informationSENSE ABOUT SCIENCE F INANCIAL STATEMENTS YEAR ENDED 5 APRIL 2005
Reg i stered Char i ty SENSE ABOUT SCIENCE F INANCIAL STATEMENTS YEAR ENDED 5 APRIL 2005 -%o i ~~ ~ aego~f ED $t~ ~ COA11Pt, l AN~. SPILKIN KNIGHT ACCOUNTANTS AND REGISTERED AUDITORS FARRIERS THE STREET
More informationSM6-36. adaptation instructions. replacing a VT. English
SM6-36 English distribution MT adaptation instructions replacing a VT SCHNEIDER ELECTRIC foreword symbols and conven ons you w ll f d all the symbols below throughout the document, nd c g the hazard levels
More informationo Alphabet Recitation
Letter-Sound Inventory (Record Sheet #1) 5-11 o Alphabet Recitation o Alphabet Recitation a b c d e f 9 h a b c d e f 9 h j k m n 0 p q k m n 0 p q r s t u v w x y z r s t u v w x y z 0 Upper Case Letter
More informationLast 4 Digits of USC ID:
Chemistry 05 B Practice Exam Dr. Jessica Parr First Letter of last Name PLEASE PRINT YOUR NAME IN BLOCK LETTERS Name: Last 4 Digits of USC ID: Lab TA s Name: Question Points Score Grader 8 2 4 3 9 4 0
More informationSM6-36. adaptation instructions. fuse blowing electrical. English. distribution HTA
SM6-36 English distribution HTA adaptation instructions fuse blowing electrical signalling SCHNEIDER ELECTRIC foreword symbols and conven ons you w ll f d all the symbols below throughout the document,
More informationTHIS PAGE DECLASSIFIED IAW E
THS PAGE DECLASSFED AW E0 2958 BL K THS PAGE DECLASSFED AW E0 2958 THS PAGE DECLASSFED AW E0 2958 B L K THS PAGE DECLASSFED AW E0 2958 THS PAGE DECLASSFED AW EO 2958 THS PAGE DECLASSFED AW EO 2958 THS
More informationMeadInterv i ew 1 Fi le : 1 Carver.doe
MeadInterv i ew 1 Fi le : 1 Carver.doe 10/00 CARVER MEAD INTERVIEW By : Gene Youngb l ood (Document 1 of 4 of Mead Interv i ew) The progress i on toward a speed/power i nvers i on has been happen i ng
More informationLinslade WRC site tour Risk Assessment
Task: Si te tour o f WRC fo r v i s i to rs People Af fected Depar tment /Area : L ins lade Water Recyc l i ng cen t re Operators N Other employees inc. contractors N Publ ic Y Assessor Name: M. Dav ies
More informationTable of C on t en t s Global Campus 21 in N umbe r s R e g ional Capac it y D e v e lopme nt in E-L e ar ning Structure a n d C o m p o n en ts R ea
G Blended L ea r ni ng P r o g r a m R eg i o na l C a p a c i t y D ev elo p m ent i n E -L ea r ni ng H R K C r o s s o r d e r u c a t i o n a n d v e l o p m e n t C o p e r a t i o n 3 0 6 0 7 0 5
More information02/05/09 Last 4 Digits of USC ID: Dr. Jessica Parr
Chemistry 05 B First Letter of PLEASE PRINT YOUR NAME IN BLOCK LETTERS Exam last Name Name: 02/05/09 Last 4 Digits of USC ID: Dr. Jessica Parr Lab TA s Name: Question Points Score Grader 2 2 9 3 9 4 2
More informationUse precise language and domain-specific vocabulary to inform about or explain the topic. CCSS.ELA-LITERACY.WHST D
Lesson eight What are characteristics of chemical reactions? Science Constructing Explanations, Engaging in Argument and Obtaining, Evaluating, and Communicating Information ENGLISH LANGUAGE ARTS Reading
More informationTHIS PAGE DECLASSIFIED IAW EO IRIS u blic Record. Key I fo mation. Ma n: AIR MATERIEL COMM ND. Adm ni trative Mar ings.
T H S PA G E D E CLA SSFED AW E O 2958 RS u blc Recod Key fo maon Ma n AR MATEREL COMM ND D cumen Type Call N u b e 03 V 7 Rcvd Rel 98 / 0 ndexe D 38 Eneed Dae RS l umbe 0 0 4 2 3 5 6 C D QC d Dac A cesson
More information8. Relax and do well.
CHEM 1515 Exam II John II. Gelder October 14, 1993 Name TA's Name Lab Section INSTRUCTIONS: 1. This examination consists of a total of 8 different pages. The last two pages include a periodic table, a
More informationRAHAMA I NTEGRATED FARMS LI MI TED RC
RAHAMA I NTEGRATED FARMS LI MI TED RC 1 0 6 2 6 3 1 CORPORATE PROFI LE ---------------------------------------------------------------------------------------- ---------------------------- Registered Name
More informationCh. 9 NOTES ~ Chemical Bonding NOTE: Vocabulary terms are in boldface and underlined. Supporting details are in italics.
Ch. 9 NOTES ~ Chemical Bonding NOTE: Vocabulary terms are in boldface and underlined. Supporting details are in italics. I. Review: Comparison of ionic and molecular compounds Molecular compounds Ionic
More informationCircle the letters only. NO ANSWERS in the Columns! (3 points each)
Chemistry 1304.001 Name (please print) Exam 4 (100 points) April 12, 2017 On my honor, I have neither given nor received unauthorized aid on this exam. Signed Date Circle the letters only. NO ANSWERS in
More informationInstruction Sheet COOL SERIES DUCT COOL LISTED H NK O. PR D C FE - Re ove r fro e c sed rea. I Page 1 Rev A
Instruction Sheet COOL SERIES DUCT COOL C UL R US LISTED H NK O you or urc s g t e D C t oroug y e ore s g / as e OL P ea e rea g product PR D C FE RES - Re ove r fro e c sed rea t m a o se e x o duct
More informationH STO RY OF TH E SA NT
O RY OF E N G L R R VER ritten for the entennial of th e Foundin g of t lair oun t y on ay 8 82 Y EEL N E JEN K RP O N! R ENJ F ] jun E 3 1 92! Ph in t ed b y h e t l a i r R ep u b l i c a n O 4 1922
More informationChemistry 1 First Lecture Exam Fall Abbasi Khajo Levine Mathias Mathias/Ortiz Metlitsky Rahi Sanchez-Delgado Vasserman
Chemistry 1 First Lecture Exam Fall 2011 Page 1 of 9 NAME Circle the name of your recitation/lab instructor(s) Abbasi Khajo Levine Mathias Mathias/Ortiz Metlitsky Rahi Sanchez-Delgado Vasserman Before
More informationLab Day and Time: Instructions. 1. Do not open the exam until you are told to start.
Name: Lab Day and Time: Instructions 1. Do not open the exam until you are told to start. 2. This exam is closed note and closed book. You are not allowed to use any outside material while taking this
More informationExecutive Committee and Officers ( )
Gifted and Talented International V o l u m e 2 4, N u m b e r 2, D e c e m b e r, 2 0 0 9. G i f t e d a n d T a l e n t e d I n t e r n a t i o n a2 l 4 ( 2), D e c e m b e r, 2 0 0 9. 1 T h e W o r
More informationSome stud i es of the app l i ca t i ons of CsI photoca thodes i n gaseous de tec tors
Nuc l ear Inst ruments and Me thods i n Phys i cs Research A 333 (1993) 391-398 Nor th-ho l l and NUCLEAR I NSTRUMENTS & METHODS IN PHYSICS RESEARCH Sec t i on A Some stud i es of the app l i ca t i ons
More informationLab Day and Time: Instructions. 1. Do not open the exam until you are told to start.
Name: Lab Day and Time: Instructions 1. Do not open the exam until you are told to start. 2. This exam is closed note and closed book. You are not allowed to use any outside material while taking this
More informationPART 1 Introduction to Theory of Solids
Elsevier UK Job code: MIOC Ch01-I044647 9-3-2007 3:03p.m. Page:1 Trim:165 240MM TS: Integra, India PART 1 Introduction to Theory of Solids Elsevier UK Job code: MIOC Ch01-I044647 9-3-2007 3:03p.m. Page:2
More informationINSTRUCTIONS: Exam III. November 10, 1999 Lab Section
CHEM 1215 Exam III John III. Gelder November 10, 1999 Name TA's Name Lab Section INSTRUCTIONS: 1. This examination consists of a total of 7 different pages. The last page includes a periodic table and
More informationCHEM 130 Exp. 8: Molecular Models
CHEM 130 Exp. 8: Molecular Models In this lab, we will learn and practice predicting molecular structures from molecular formulas. The Periodic Table of the Elements IA 1 H IIA IIIA IVA VA VIA VIIA 3 5
More informationProgression in calculations Years 3 and 4
Progression in calculations Years 3 and 4 Introduction At the centre of the mastery approach to the teaching of mathematics is the belief that all pupils have the potential to succeed. They should have
More informationPERMACULTURA INTENSIVE EDE. 3weeks,intensivetraining
HEL L O!! T hankf orded ca ng a f ew m nu ef oruand f ora he uppor you can of f er. F r om he 5 hofnovember o he 22nd ofnovember201 4,we ar e go ng o of f eran n en ve wor k hop r e a ed o he env r onmenand
More information8. Relax and do well.
CHEM 15 Exam II John II. Gelder March 4, 1999 Name TA's Name Lab Section INSTRUCTIONS: 1. This examination consists of a total of 7 different pages. The last two pages includes a periodic table, a solubility
More informationLab Day and Time: Instructions. 1. Do not open the exam until you are told to start.
Name: Lab Day and Time: Instructions 1. Do not open the exam until you are told to start. 2. This exam is closed note and closed book. You are not allowed to use any outside material while taking this
More informationCircle the letters only. NO ANSWERS in the Columns!
Chemistry 1304.001 Name (please print) Exam 5 (100 points) April 18, 2018 On my honor, I have neither given nor received unauthorized aid on this exam. Signed Date Circle the letters only. NO ANSWERS in
More informationI N A C O M P L E X W O R L D
IS L A M I C E C O N O M I C S I N A C O M P L E X W O R L D E x p l o r a t i o n s i n A g-b eanste d S i m u l a t i o n S a m i A l-s u w a i l e m 1 4 2 9 H 2 0 0 8 I s l a m i c D e v e l o p m e
More informationSMOOTH WALLBATHWARE. escape the ordinary. aquariusproducts.com
SMOOTH WALLBATHWARE escape the ordinary aquariusproducts.com escape SMOOTH WALLBATHWARE premium residential bathware the ordinary Create a unique look and feel with Aquarius Smooth Wall bathware. AcrylX
More informationThe Periodic Table. Periodic Properties. Can you explain this graph? Valence Electrons. Valence Electrons. Paramagnetism
Periodic Properties Atomic & Ionic Radius Energy Electron Affinity We want to understand the variations in these properties in terms of electron configurations. The Periodic Table Elements in a column
More informationAtoms and the Periodic Table
Atoms and the Periodic Table Parts of the Atom Proton Found in the nucleus Number of protons defines the element Charge +1, mass 1 Parts of the Atom Neutron Found in the nucleus Stabilizes the nucleus
More information8. Relax and do well.
CHEM 1225 Exam I John I. Gelder February 4, 1999 Name KEY TA's Name Lab Section Please sign your name below to give permission to post your course scores on homework, laboratories and exams. If you do
More informationCOMPILATION OF AUTOMATA FROM MORPHOLOGICAL TWO-LEVEL RULES
Kimmo Koskenniemi Re se ar ch Unit for Co mp ut at io na l Li ng ui st ic s University of Helsinki, Hallituskatu 11 SF-00100 Helsinki, Finland COMPILATION OF AUTOMATA FROM MORPHOLOGICAL TWO-LEVEL RULES
More informationElement Cube Project (x2)
Element Cube Project (x2) Background: As a class, we will construct a three dimensional periodic table by each student selecting two elements in which you will need to create an element cube. Helpful Links
More informationPERIODIC TABLE OF THE ELEMENTS
Useful Constants and equations: K = o C + 273 Avogadro's number = 6.022 x 10 23 d = density = mass/volume R H = 2.178 x 10-18 J c = E = h = hc/ h = 6.626 x 10-34 J s c = 2.998 x 10 8 m/s E n = -R H Z 2
More information(C) Pavel Sedach and Prep101 1
(C) Pavel Sedach and Prep101 1 (C) Pavel Sedach and Prep101 1 (C) Pavel Sedach and Prep101 2 (C) Pavel Sedach and Prep101 2 (C) Pavel Sedach and Prep101 3 (C) Pavel Sedach and Prep101 3 (C) Pavel Sedach
More informationInstructions. 1. Do not open the exam until you are told to start.
Name: Lab Day and Time: Instructions 1. Do not open the exam until you are told to start. 2. This exam is closed note and closed book. You are not allowed to use any outside material while taking this
More informationSenility Degree. Our machine derives APG waveform after 2 nd differential of arterial pulse wave in order to measure
Senility Degree Our machine derives APG waveform after 2 nd differential of arterial pulse wave in order to measure 1. Cardiac Eccentric Constriction Power 2. Arterial Elasticity 3. Remaining blood volume
More informationO. B. S H I M E, Q. C.
I N T H E MATT E R O F A N AR B I T RAT I O N B ETWE E N : O NTA R I O P RO P E RTY AS S ES S M E N T C O R PO RAT I O N AN D : O N TA R I O P U B L I C S E RV I C E E M P LOY E E S ' U N I O N A N D I
More informationI M P O R T A N T S A F E T Y I N S T R U C T I O N S W h e n u s i n g t h i s e l e c t r o n i c d e v i c e, b a s i c p r e c a u t i o n s s h o
I M P O R T A N T S A F E T Y I N S T R U C T I O N S W h e n u s i n g t h i s e l e c t r o n i c d e v i c e, b a s i c p r e c a u t i o n s s h o u l d a l w a y s b e t a k e n, i n c l u d f o l
More informationSecondary Support Pack. be introduced to some of the different elements within the periodic table;
Secondary Support Pack INTRODUCTION The periodic table of the elements is central to chemistry as we know it today and the study of it is a key part of every student s chemical education. By playing the
More information7. Relax and do well.
CHEM 1215 Exam II John II. Gelder October 7, 1998 Name TA's Name Lab Section INSTRUCTIONS: 1. This examination consists of a total of 5 different pages. The last page includes a periodic table and a solubility
More informationChem Exam 1. September 26, Dr. Susan E. Bates. Name 9:00 OR 10:00
Chem 1711 Exam 1 September 26, 2013 Dr. Susan E. Bates Name 9:00 OR 10:00 N A = 6.022 x 10 23 mol 1 I A II A III B IV B V B VI B VII B VIII I B II B III A IV A V A VI A VII A inert gases 1 H 1.008 3 Li
More informationChemistry 2 Exam Roane State Academic Festival. Name (print neatly) School
Name (print neatly) School There are fifteen question on this exam. Each question is weighted equally. n the answer sheet, write your name in the space provided and your answers in the blanks provided.
More informationNAME: FIRST EXAMINATION
1 Chemistry 64 Winter 1994 NAME: FIRST EXAMINATION THIS EXAMINATION IS WORTH 100 POINTS AND CONTAINS 4 (FOUR) QUESTIONS THEY ARE NOT EQUALLY WEIGHTED! YOU SHOULD ATTEMPT ALL QUESTIONS AND ALLOCATE YOUR
More information8. Relax and do well.
CHEM 1215 Exam III John III. Gelder November 11, 1998 Name TA's Name Lab Section INSTRUCTIONS: 1. This examination consists of a total of 7 different pages. The last page includes a periodic table and
More informationSolutions and Ions. Pure Substances
Class #4 Solutions and Ions CHEM 107 L.S. Brown Texas A&M University Pure Substances Pure substance: described completely by a single chemical formula Fixed composition 1 Mixtures Combination of 2 or more
More informationSM6-36. d str but on HTA. motor sat on of a CIT operat ng mechan sm
SM6-36 d str but on HTA on motor sat on of a CIT operat ng mechan sm SCHNEIDER ELECTRIC foreword symbols and conven ons you w ll f d all the symbols below throughout the document, nd c g the hazard levels
More informationCHEM 10113, Quiz 5 October 26, 2011
CHEM 10113, Quiz 5 October 26, 2011 Name (please print) All equations must be balanced and show phases for full credit. Significant figures count, show charges as appropriate, and please box your answers!
More informationLab Day and Time: Instructions. 1. Do not open the exam until you are told to start.
Name: Lab Day and Time: Instructions 1. Do not open the exam until you are told to start. 2. This exam is closed note and closed book. You are not allowed to use any outside material while taking this
More informationGuide to the Extended Step-Pyramid Periodic Table
Guide to the Extended Step-Pyramid Periodic Table William B. Jensen Department of Chemistry University of Cincinnati Cincinnati, OH 452201-0172 The extended step-pyramid table recognizes that elements
More information5 questions, 3 points each, 15 points total possible. 26 Fe Cu Ni Co Pd Ag Ru 101.
Physical Chemistry II Lab CHEM 4644 spring 2017 final exam KEY 5 questions, 3 points each, 15 points total possible h = 6.626 10-34 J s c = 3.00 10 8 m/s 1 GHz = 10 9 s -1. B= h 8π 2 I ν= 1 2 π k μ 6 P
More informationGen ova/ Pavi a/ Ro ma Ti m i ng Count er st at Sep t. 2004
Ti m i ng Count er st at us @ Sep t. 2004 1 Ti m i n g Cou n t er act i vi t i es Ti m i n g r esol u t i on : 100 p s FWHM h ave b een ach i eved. PM s ch ar act er ised i n t h e COBRA m ag n et f or
More information_ J.. C C A 551NED. - n R ' ' t i :. t ; . b c c : : I I .., I AS IEC. r '2 5? 9
C C A 55NED n R 5 0 9 b c c \ { s AS EC 2 5? 9 Con 0 \ 0265 o + s ^! 4 y!! {! w Y n < R > s s = ~ C c [ + * c n j R c C / e A / = + j ) d /! Y 6 ] s v * ^ / ) v } > { ± n S = S w c s y c C { ~! > R = n
More information610B Final Exam Cover Page
1 st Letter of Last Name NAME: 610B Final Exam Cover Page No notes or calculators of any sort allowed. You have 3 hours to complete the exam. CHEM 610B, 50995 Final Exam Fall 2003 Instructor: Dr. Brian
More informationFr anchi s ee appl i cat i on for m
Other Fr anchi s ee appl i cat i on for m Kindly fill in all the applicable information in the spaces provided and submit to us before the stipulated deadline. The information you provide will be held
More informationCHEM 167 FINAL EXAM MONDAY, MAY 2 9:45 11:45 A.M GILMAN HALL
PROF. JOHN VERKADE SPRING 2005 THIS EXAM CONSISTS OF 12 QUESTIONS ON 9 PAGES CHEM 167 HOUR EXAM IV APRIL 20, 2005 SEAT NO. NAME RECIT. INSTR. RECIT. SECT. GRADING PAGE Page 2 Page 3 Page 4 Page 5 Page
More informationChapter 3: Stoichiometry
Chapter 3: Stoichiometry Chem 6A Michael J. Sailor, UC San Diego 1 Announcements: Thursday (Sep 29) quiz: Bring student ID or we cannot accept your quiz! No notes, no calculators Covers chapters 1 and
More informationCHEM Come to the PASS workshop with your mock exam complete. During the workshop you can work with other students to review your work.
It is most beneficial to you to write this mock midterm UNDER EXAM CONDITIONS. This means: Complete the midterm in 1.5 hours. Work on your own. Keep your notes and textbook closed. Attempt every question.
More informationM10/4/CHEMI/SPM/ENG/TZ2/XX+ CHEMISTRY. Wednesday 12 May 2010 (afternoon) 45 minutes INSTRUCTIONS TO CANDIDATES
M10/4/CHEMI/SPM/ENG/TZ/XX+ 106116 CHEMISTRY standard level Paper 1 Wednesday 1 May 010 (afternoon) 45 minutes INSTRUCTIONS TO CANDIDATES Do not open this examination paper until instructed to do so. Answer
More informationPOLYTECHNIC OF NAMIBIA
POLYTECHNIC OF NAMIBIA DEPARTMENT OF HEALTH SCIENCES BACHELOR OF ENVIRONMENTAL HEALTH SCIENCES HEALTH SCIENCE CHEMISTRY (HSC 511S) NQF level 5 SECOND OPPORTUNITY EXAMINATION November 2014 TIME: MARKS:
More informationCLASS TEST GRADE 11. PHYSICAL SCIENCES: CHEMISTRY Test 4: Matter and materials 1
CLASS TEST GRADE PHYSICAL SCIENCES: CHEMISTRY Test 4: Matter and materials MARKS: 45 TIME: hour INSTRUCTIONS AND INFORMATION. Answer ALL the questions. 2. You may use non-programmable calculators. 3. You
More informationInstructions. 1. Do not open the exam until you are told to start.
Name: Lab Day and Time: Instructions 1. Do not open the exam until you are told to start. 2. This exam is closed note and closed book. You are not allowed to use any outside material while taking this
More informationSPECIFICATION SHEET : WHSG4-UNV-T8-HB
SPECIFICATION SHEET : WHSG4UNVT8HB ELECTRICAL DATA (120V APPLICATION) INPUT VO LT : 120V ± 10%, 50/60H z LAM P W ATTS/T YPE F17T8 F25T8 F30T8 F 32T8 F32T 8( 25W ) F32T8(28W ) F32T8(30W ) FB31T 8 FB32T8
More information30 Zn(s) 45 Rh. Pd(s) Ag(s) Cd(s) In(s) Sn(s) white. 77 Ir. Pt(s) Au. Hg(l) Tl. 109 Mt. 111 Uuu. 112 Uub. 110 Uun. 65 Tb. 62 Sm. 64 Gd. 63 Eu.
Enthalpy changes: experimentally it is much easier to measure heat flow at const pressure - this is enthalpy q p = )H : also nearly all chemical reactions are done at constant pressure. Enthalpy (heat)
More informationCATAVASII LA NAȘTEREA DOMNULUI DUMNEZEU ȘI MÂNTUITORULUI NOSTRU, IISUS HRISTOS. CÂNTAREA I-A. Ήχος Πα. to os se e e na aș te e e slă ă ă vi i i i i
CATAVASII LA NAȘTEREA DOMNULUI DUMNEZEU ȘI MÂNTUITORULUI NOSTRU, IISUS HRISTOS. CÂNTAREA I-A Ήχος α H ris to os s n ș t slă ă ă vi i i i i ți'l Hris to o os di in c ru u uri, în tâm pi i n ți i'l Hris
More informationLab Day and Time: Instructions. 1. Do not open the exam until you are told to start. Page # Points possible Points awarded
Name: Lab Day and Time: Instructions 1. Do not open the exam until you are told to start. 2. This exam is closed note and closed book. You are not allowed to use any outside material while taking this
More informationUse precise language and domain-specific vocabulary to inform about or explain the topic. CCSS.ELA-LITERACY.WHST D
Lesson seven What is a chemical reaction? Science Constructing Explanations, Engaging in Argument and Obtaining, Evaluating, and Communicating Information ENGLISH LANGUAGE ARTS Reading Informational Text,
More informationHANDOUT SET GENERAL CHEMISTRY II
HANDOUT SET GENERAL CHEMISTRY II Periodic Table of the Elements 1 2 3 4 5 6 7 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 IA VIIIA 1 2 H He 1.00794 IIA IIIA IVA VA VIA VIIA 4.00262 3 Li 6.941 11 Na 22.9898
More informationAT LAST!! CAGE CODE 6CVS2. SandMaster 20 for Skid Steers THE FUTURE OF EMERGENCY FLOOD CONTROL HAS ARRIVED.
SandMaster 20 for Skid Steers AT LAST!! THE FUTURE OF EMERGENCY FLOOD CONTROL HAS ARRIVED. Hydraulic technology replaces hand labor for fast and efficient on site filling and placement of sandbags. Fill
More informationROAD INVENTORY FOR CERTIFICATION OF MILEAGE
ROD INVENTORY FOR CERTIFICTION OF MILEGE Kay F outs Road Inventory Supervisor, IS H C ISHC ROD IN V E N T O R Y SECTIO N ND DT C O L L E C T IO N s provided in the Indiana Code, the Indiana State Highway
More informationRadiometric Dating (tap anywhere)
Radiometric Dating (tap anywhere) Protons Neutrons Electrons Elements on the periodic table are STABLE Elements can have radioactive versions of itself called ISOTOPES!! Page 1 in your ESRT has your list!
More informationLesson Ten. What role does energy play in chemical reactions? Grade 8. Science. 90 minutes ENGLISH LANGUAGE ARTS
Lesson Ten What role does energy play in chemical reactions? Science Asking Questions, Developing Models, Investigating, Analyzing Data and Obtaining, Evaluating, and Communicating Information ENGLISH
More informationWelcome to the Public Meeting Red Bluff Road from Kirby Boulevard to State Highway 146 Harris County, Texas CSJ No.: December 15, 2016
Welcome to the Public Meeting Red Bluff Road from Kirby Boulevard to State Highway 146 Harris County, Texas CSJ No.: 0912-72-340 December 15, 2016 No formal presentation will be made. Seabrook Intermediate
More informationChem 112, Fall 05 Exam 2a
Name: YOU MUST: Put your name and student ID on the bubble sheet correctly. Put all your answers on the bubble sheet. Please sign the statement on the last page of the exam. Please make sure your exam
More informationCMSC 313 Lecture 17 Postulates & Theorems of Boolean Algebra Semiconductors CMOS Logic Gates
CMSC 313 Lecture 17 Postulates & Theorems of Boolean Algebra Semiconductors CMOS Logic Gates UMBC, CMSC313, Richard Chang Last Time Overview of second half of this course Logic gates &
More informationCHEM 10123/10125, Exam 2
CHEM 10123/10125, Exam 2 March 7, 2012 (50 minutes) Name (please print) Please box your answers, and remember that significant figures, phases (for chemical equations), and units do count! 1. (13 points)
More information(please print) (1) (18) H IIA IIIA IVA VA VIA VIIA He (2) (13) (14) (15) (16) (17)
CHEM 10113, Quiz 3 September 28, 2011 Name (please print) All equations must be balanced and show phases for full credit. Significant figures count, show charges as appropriate, and please box your answers!
More informationThe Periodic Table of the Elements
The Periodic Table of the Elements All matter is composed of elements. All of the elements are composed of atoms. An atom is the smallest part of an element which still retains the properties of that element.
More information7. Relax and do well.
CHEM 1215 Exam II John II. Gelder October 13, 1999 Name TA's Name Lab Section INSTRUCTIONS: 1. This examination consists of a total of 5 different pages. The last page includes a periodic table and a solubility
More information8. Relax and do well.
CHEM 34.02 and 34.03 Name Exam III John III. Gelder TA's Name November 5, 2000 Lab Section INSTRUCTIONS:. This examination consists of a total of 9 different pages. The last three pages include a periodic
More information8. Relax and do well.
CHEM 1225 Exam III John III. Gelder April 8, 1999 Name TA's Name Lab Section INSTRUCTIONS: 1. This examination consists of a total of 7 different pages. The last two pages includes a periodic table and
More informationCHM 101 PRACTICE TEST 1 Page 1 of 4
CHM 101 PRACTICE TEST 1 Page 1 of 4 Please show calculations (stuffed equations) on all mathematical problems!! On the actual test, "naked answers, with no work shown, will receive no credit even if correct.
More informationBROOKLYN COLLEGE Department of Chemistry. Chemistry 1 Second Lecture Exam Nov. 27, Name Page 1 of 5
BROOKLYN COLLEGE Department of Chemistry Chemistry 1 Second Lecture Exam Nov. 27, 2002 Name Page 1 of 5 Circle the name of your lab instructor Kobrak, Zhou, Girotto, Hussey, Du Before you begin the exam,
More informationM1 a. So there are 4 cases from the total 16.
M1 a. Remember that overflow is defined as the result of the operation making no sense, which in 2's complement representa tion is equivalent to the mathematical result not fitting in the format. if any
More information